Introduction to Sodium Hyaluronate

Sodium hyaluronate has a history of nearly 80 years since its discovery. As early as 1934, Meyer and Palmer isolated a polymer containing uronic acid and hexosamine from the hyaloid body. Polysaccharide, named "hyaluronic acid". The word is a combination of "hyaloid" (transparent, glassy) and "uronic acid", "Biochemical Noun" is translated as "hyaluronic acid", "Chinese Pharmacopoeia" and national drug standards are called "hyaluronic acid" ". In a physiologically neutral environment, hyaluronic acid is a polyanion. In 1985, Balazs et al. suggested using the term hyaluronan to name the substance uniformly. The reason is that the substance is essentially a carbohydrate and should be named according to its glycosaminoglycan naming rules, that is, the suffix an is used. "Hyaluronan" has been widely used, covering any state of hyaluronic acid and its salts (hyaluronate), usually translated as "hyaluronic acid", abbreviated as HA. At present, HA products with the drug standard are usually called "sodium hyaluronate injection", and HA products with the drug standard are called medical sodium hyaluronate gel. As early as the late 1970s, the United States first developed the first product of this substance that could be used in human clinical practice. Since this product is used for ophthalmic microsurgery-cataract surgery, its main function is that clinicians act as ophthalmic microscopy Surgical pads are used as a temporary support for the operation space to facilitate the smooth implementation of the operation. Therefore, they are approved and sold on the market. Subsequently, this product has come out in orthopedics and surgery, all of which are sold under the instrument number. Therefore, the FDA in the United States recognized the substance as a medical device.